Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor EventsGlobeNewsWire • 02/21/24
Wall Street Analysts Believe Editas (EDIT) Could Rally 80%: Here's is How to TradeZacks Investment Research • 02/19/24
Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)Seeking Alpha • 02/13/24
Editas Medicine, Inc. (EDIT) Guggenheim 6th Annual Biotechnology Conference (Transcript)Seeking Alpha • 02/07/24
Editas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)Seeking Alpha • 01/10/24
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/24
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Vertias's $100M deal to license Editas IP sets a precedent for gene-editing therapy developers in the USProactive Investors • 12/13/23
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9GlobeNewsWire • 12/13/23
Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript)Seeking Alpha • 12/11/23
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored WebinarGlobeNewsWire • 12/11/23